Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 6.47
LIFE's Cash-to-Debt is ranked lower than
59% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. LIFE: 6.47 )
Ranked among companies with meaningful Cash-to-Debt only.
LIFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54  Med: 19.24 Max: N/A
Current: 6.47
Interest Coverage N/A
LIFE's Interest Coverage is ranked lower than
64% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LIFE: N/A )
Ranked among companies with meaningful Interest Coverage only.
LIFE' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: N/A
Current: N/A
Piotroski F-Score: 3
Altman Z-Score: -3.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -73.66
LIFE's ROE % is ranked lower than
69% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. LIFE: -73.66 )
Ranked among companies with meaningful ROE % only.
LIFE' s ROE % Range Over the Past 10 Years
Min: -399.23  Med: -232.15 Max: -65.06
Current: -73.66
-399.23
-65.06
ROA % -61.61
LIFE's ROA % is ranked lower than
73% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. LIFE: -61.61 )
Ranked among companies with meaningful ROA % only.
LIFE' s ROA % Range Over the Past 10 Years
Min: -80.59  Med: -59.44 Max: -50.3
Current: -61.61
-80.59
-50.3
ROC (Joel Greenblatt) % -3335.11
LIFE's ROC (Joel Greenblatt) % is ranked lower than
77% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. LIFE: -3335.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LIFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3605.48  Med: -1812.39 Max: -780.12
Current: -3335.11
-3605.48
-780.12
GuruFocus has detected 3 Warning Signs with aTyr Pharma Inc $LIFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LIFE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:VSTM, OTCPK:SLNCF, AMEX:RNN, NAS:AFMD, OTCPK:NURPF, NAS:ARQL, NAS:NTEC, NAS:INFI, NAS:BLRX, NAS:FLKS, NAS:NVIV, NAS:BCLI, OTCPK:MCUJF, NAS:APEN, OTCPK:ARTH, AMEX:NAVB, NAS:NVET, OTCPK:FENCF, OTCPK:IPIX, NAS:MRTX » details
Traded in other countries:471.Germany,
Headquarter Location:USA
aTyr Pharma Inc is engaged in the discovery and clinical development of medicines for patients suffering from diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.

aTyr Pharma Inc was incorporated in the state of Delaware on September 8, 2005. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The Company is currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the European Union. This randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple intravenous doses of Resolaris in adults with FSHD. Its initial therapeutic efforts target severe, rare disease indications in which patients suffer from the immune-related consequences of their genetic disease. It contracts with third parties for the manufacturing and testing of its product candidates for preclinical studies and clinical trials. It does not own or operate manufacturing facilities for the production of clinical quantities of its product candidates. Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical and biological products, such as those it is developing.

Ratios

vs
industry
vs
history
PB Ratio 1.70
LIFE's PB Ratio is ranked higher than
80% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. LIFE: 1.70 )
Ranked among companies with meaningful PB Ratio only.
LIFE' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.75
Current: 1.7
0
1.75
EV-to-EBIT -0.63
LIFE's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. LIFE: -0.63 )
Ranked among companies with meaningful EV-to-EBIT only.
LIFE' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.67  Med: 0 Max: 0
Current: -0.63
-0.67
0
EV-to-EBITDA -0.64
LIFE's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. LIFE: -0.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
LIFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.68  Med: 0 Max: 0
Current: -0.64
-0.68
0
Current Ratio 9.74
LIFE's Current Ratio is ranked higher than
78% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. LIFE: 9.74 )
Ranked among companies with meaningful Current Ratio only.
LIFE' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 7.35 Max: 12.69
Current: 9.74
1.63
12.69
Quick Ratio 9.74
LIFE's Quick Ratio is ranked higher than
79% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. LIFE: 9.74 )
Ranked among companies with meaningful Quick Ratio only.
LIFE' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 7.35 Max: 12.69
Current: 9.74
1.63
12.69

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.85
LIFE's Price-to-Net-Cash is ranked higher than
89% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. LIFE: 1.85 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LIFE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.94  Med: 1.55 Max: 4.9
Current: 1.85
0.94
4.9
Price-to-Net-Current-Asset-Value 1.78
LIFE's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. LIFE: 1.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LIFE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.9  Med: 1.5 Max: 4.74
Current: 1.78
0.9
4.74
Price-to-Tangible-Book 1.71
LIFE's Price-to-Tangible-Book is ranked higher than
84% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. LIFE: 1.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LIFE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 1.33 Max: 3.14
Current: 1.71
0.76
3.14
Earnings Yield (Greenblatt) % -158.69
LIFE's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. LIFE: -158.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LIFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -674.59  Med: 0 Max: 13069.07
Current: -158.69
-674.59
13069.07

More Statistics

EPS (TTM) $ -2.32
Short Percentage of Float4.20%
52-Week Range $2.10 - 4.45
Shares Outstanding (Mil)23.81
» More Articles for LIFE

Headlines

Articles On GuruFocus.com
Uncovering Value in the Metals and Mining Sector Jun 26 2017 
Seeking Value in China: Great Wall Motor Jun 26 2017 
Vaccine Small-Cap Just Took a Big Step Forward Jun 26 2017 
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Oracle Slowly Gaining Momentum on the Cloud Front Jun 26 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 

More From Other Websites
aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference May 31 2017
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the... May 15 2017
Atyr Pharma reports 1Q loss May 11 2017
aTyr Pharma Announces First Quarter 2017 Operating Results May 11 2017
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular... Apr 24 2017
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in... Apr 24 2017
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors Apr 10 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors Apr 03 2017
aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived... Mar 15 2017
aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy... Mar 03 2017
aTyr Pharma Rises 16% on Orphan Drug Status Mar 01 2017
aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference Mar 01 2017
aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular... Feb 28 2017
High court ruling limits international reach of patent laws Feb 22 2017
Atyr Pharma Stock Spikes 33% on FDA Updates Jan 19 2017
FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B... Jan 18 2017
Roberts recuses from patent case after discovering conflict Jan 04 2017
Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares Dec 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}